louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03636009: Concurrent Treatment for Patients With Cervical Radiculopathy
Official title: The Concurrent Use of Intermittent Cervical Traction and Neuromobilization Techniques in Patients With Cervical Radiculopathy
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Spinal Nerve Root Disorder Nos
Keywords: cervical radiculopathy
neck pain
neuromobilizations
Lead sponsor: University of Indianapolis
Sponsor class: OTHER
First posted: 2018-08-17
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Two groups receiving interventions
Primary purpose: TREATMENT

Brief summary: This study evaluates the effectiveness of two treatment interventions in patients with cervical radiculopathy. One group will receive a concurrent approach using traction and neuromobilizations. The other group will receive the sequential approach of traction and neuromobilizations

Detailed description: Physical therapists routinely use cervical traction and manual therapy in patients with cervical radiculopathy. The standard of care is a sequential approach in which the patients receive interventions successively. This study will provide the standard of care approach for one group while the other group receives the concurrent approach in which the patient will have neuromobilizations while they are receiving mechanical traction. Both groups will also receive exercise and manual therapy to the cervical and thoracic spine.

Eligibility criteria: Inclusion criteria:

* Participants that test positive on at least 3 out of 4 special tests.
* Participants will score at least 10 on the Neck Disability Index
* Participants will score at least 2 on the numeric pain rating scale

Exclusion Criteria:

* Do not test positive on at least 3 of 4 special tests.
* Signs of cervical trauma
* Cervical myelopathy
* Active pregnancy
* Medical red flags (fracture, tumor, long term steroid use, rheumatoid arthritis, and osteoporosis)
* Evidence of vascular compromise
* Cervical spine surgery
* Recent injections in the past six weeks

Primary outcomes:
measure: changes in pain
timeFrame: after 4 weeks of intervention
measure: changes in function
timeFrame: After 4 weeks of intervention
Secondary outcomes:
measure: Difference in treatment time between the groups
timeFrame: 4 weeks of intervention
Other outcomes:
Locations:
city: Mishawaka
country: United States
facility: Michiana Orthopaedics and Sports Physical Therapy
state: Indiana
Study officials:
affiliation: University of Indianapolis
name: James Bellew, EdD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01324609: Detection of Choroidal Nevus Cells in Vitrectomy Fluid
Official title: Detection of Choroidal Nevus Cells in Vitrectomy Fluid
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Nevus
Keywords: choroidal nevus
vitrectomy
Lead sponsor: Stanford University
Sponsor class: OTHER
First posted: 2011-03-29
Enrollment: 2
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with a choroidal nevus who are undergoing routine vitrectomy surgery for another indication.

Brief summary: The purpose of this study is to determine if the investigators can detect the presence of choroidal nevi cells in the vitreous fluid of humans, as this may improve the diagnosis and classification of choroidal nevi and melanomas in the future.

Detailed description: Approximately 7% of the population has a choroidal nevus, or "freckle," in the back of the eye. Like a nevus on the skin, there is potential for malignant change to a melanoma. Dermatologists have the ability to quickly and easily biopsy suspicious skin lesions while ophthalmologists currently have no way of determining the malignant potential of choroidal nevi other than a fine needle aspiration (which is invasive and has the potential complications of bleeding and retinal detachment). This study's sole aim is to see if choroidal nevi cells are present in the inside fluid of the eye. The investigators plan to analyze the fluid of the eye, which is routinely removed during retina surgery, to detect any nevus cells. If the investigators are able to detect these cells, then future studies may allow us to better classify choroidal nevi for potential malignant change.

Eligibility criteria: Inclusion Criteria:

* Patients with a choroidal nevus who are undergoing routine vitrectomy surgery for another indication (such as epiretinal membrane or macular hole repair).

Exclusion Criteria:

* Patients without a choroidal nevus
* Children under the age of 18
* Pregnant and nursing females

Primary outcomes:
measure: Positive identification of nevus cells in eye fluid
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: Stanford
country: United States
facility: Stanford University School of Medicine
state: California
Study officials:
affiliation: Stanford University
name: Dr. Darius M. Moshfeghi
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00857909: The Effect of Amiloride and Spironolactone in Healthy Persons
Official title: The Effect of Amiloride and Spironolactone Measured on Cardiovascular and Kidney Related Variables in Healthy Subjects in a Double-blinded, Randomised, Placebo-controlled, Cross-over Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: High Blood Pressure
Lead sponsor: Regional Hospital Holstebro
Sponsor class: OTHER
First posted: 2009-03-09
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: This study will investigate whether retaining potassium in the body will lead to changes in blood pressure and changes in blood and urine samples.

Detailed description: The purpose is to measure the effect of amiloride and spironolactone on:

1. Renal function (GFR, u-AQP2, u-ENaCβ, u-cAMP, u-PGE2, CH20, FENa, FEK),
2. Pulsbewave velocity, augmentation index and central blood pressure,
3. Vasoactive hormones (PRC, AngII, Aldo, AVP, ANP, BNP and Endot), and
4. Ambulatory blood pressure

Eligibility criteria: Inclusion Criteria:

* Healthy
* Non-smokers

Exclusion Criteria:

* Smoking
* Under medical treatment

Primary outcomes:
measure: Blood pressure
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Holstebro
country: Denmark
facility: Medical Research
Study officials:
affiliation: Regional Hospital Holstebro
name: Erling B Pedersen, Prof
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05953909: A Study of Eribulin-Based Regimen Versus Other Chemotherpy in Triple-Negative Metastatic Breast Cancer (ERI-Based-01).
Official title: Efficacy and Safety of Eribulin-Based Regimen in the Treatment of Metastatic Triple-Negative Breast Cancer and Comparison With Other Chemotherapy Regimen: A Single-Center Retrospective Study
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Breast Cancer
Lead sponsor: Fujian Cancer Hospital
Sponsor class: OTHER_GOV
First posted: 2023-07-20
Enrollment: 120
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The pathologic diagnosis is unresectable recurrent or metastatic triple-negative Chinese Breast cancer patients.

Brief summary: A Single-Center Retrospective Study About Efficacy and Safety of Eribulin-Based Regimen in the Treatment of Metastatic Triple-Negative Breast Cancer and Comparison With Other Chemotherapy Regimen

Detailed description: Not provided

Eligibility criteria: Inclusion Criteria:

1. Women aged 18-70.
2. The pathologic diagnosis of unresectable recurrent or metastatic triple-negative breast cancer ［ER-negative(IHC\<1%), PR-negative(IHC\<1%), HER2-negative（IHC-/+ or IHC++ and FISH/CISH-）］.
3. Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2.
4. Patients with at least one measuring lesion that was conformed to RECIST v1.1 standard.
5. Patients receiving eribulin-based therapy received at least two cycles of eribulin-based chemotherapy. Eribulin was treated until disease progression, unacceptable toxicity or patient refusal of treatment.
6. Adverse events were recorded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE 5.0).

Exclusion Criteria:

1. Patients previously treated with eribulin.
2. Patients with grade ≥3 adverse events did not recover according to CTCAE 5.0 criteria.
3. Not applicable to combined chemotherapy, or allergic or intolerant to related drugs.

Primary outcomes:
measure: Progression free surviva (PFS)
timeFrame: up to 24 months
measure: Overall survival (OS)
timeFrame: up to 24 months
Secondary outcomes:
measure: Overall response rate (ORR)
timeFrame: 12 months
measure: Disease Control Rate (DCR)
timeFrame: 12 months
measure: Incidence of adverse events
timeFrame: 12 months
Other outcomes:
Locations:
city: Fuzhou
country: China
facility: Fujian Cancer Hospital
state: Fujian
Study officials:
affiliation: Fujian Cancer Hospital
name: weiwei Huang
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06883409: Laparoscopic Interval Cytoreductive Surgery in Advance Ovarian Cancer
Official title: Efficiency of Laparoscopic Interval Cytoreductive Surgery After Neoadjuvant Chemotherapy in Patients With Stage III and IV Epithelial Ovarian Cancer
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Ovarian Neoplasms
Keywords: Minimal invasive surgery
interval debulking surgery
advance ovarian cancer
Lead sponsor: Instituto Nacional de Cancerologia de Mexico
Sponsor class: OTHER
First posted: 2025-03-19
Enrollment: 33
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: A prospective single-arm phase II clinical trial study was conducted. We evaluated the efficacy and complications of interval laparoscopic cytoreduction in patients with COEA after NCT. Patients diagnosed with advanced ovarian carcinoma who received 3 to 4 cycles of NCT using carboplatin/paclitaxel with or without bevacizumab were included. Interval cytoreductive laparoscopic surgery was performed.
Primary purpose: TREATMENT

Brief summary: This is a study that aims to demonstrate the non-inferiority of minimally invasive surgery versus open surgery, as an approach for patients with advanced ovarian cancer who received neoadjuvant chemotherapy, giving them the benefits of laparoscopic surgery. This way they can continue with their complementary treatment.


Eligibility criteria: Inclusion Criteria:

* Diagnosis of epithelial ovarian cancer (all subtypes of epithelial ovarian cancer) in stage III-IV
* Partial and complete response to treatment with QTNA after 3-4 cycles, evaluated by PET-CT imaging study, patients that the functional unit decides to incorporate into the project.
* Ca 125 which will have to be less than 200
* ECOG 0 to 2 without medical contraindication to perform surgery (≤ ASA 2 or ≤ Goldman 2).

Exclusion Criteria:

* Partial response with persistence of ascites or pleural effusion.
* With unresectability criteria (multiple intrahepatic liver metastases, retroperitoneal lymph node conglomerates \>2cm above the renal lymph nodes, metastatic disease above the diaphragm, multiple intestinal involvement and mesentery retraction).

Primary outcomes:
measure: Efficiency of Laparoscopic Interval Cytoreductive Surgery After Neoadjuvant Chemotherapy in Patients with Stage III and IV Epithelial Ovarian Cancer
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: México City
country: Mexico
facility: Instituto Nacional de Cancerologia
state: Tlalpan
Study officials:
References:
Clinical trial NCT04793009: Prophylactic Funnel Mesh to Prevent Parastomal Hernia in Permanent End Colostomy After Abdomino-perineal Resection
Official title: Prophylactic Funnel Mesh to Prevent Parastomal Hernia in Permanent End Colostomy: A Retrospective Cohort Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hernia
Colostomy Stoma
Lead sponsor: Cantonal Hospital of St. Gallen
Sponsor class: OTHER
First posted: 2021-03-11
Enrollment: 76
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients receiving elective abdominoperineal resection between January 2013 and December 2018 at the Cantonal Hospital of St. Gallen

Brief summary: This retrospective study asses if a prophylactic, funnel-shaped, intraperitoneal mesh prevents parastomal hernia in patients undergoing abdominoperineal rectum resection with permanent end colostomy.


Eligibility criteria: Inclusion Criteria:

* elecitve abdominoperineal resection

Exclusion Criteria:

* rejection of a retrospective data Analysis
* age under 18 years
* meshes other than the funnel-shaped mesh

Primary outcomes:
measure: Occurrence of parastomal hernia
timeFrame: initial operation until an avarage of 3 years
Secondary outcomes:
measure: Reoperations due to parastomal hernia
timeFrame: initial operation until an avarage of 3 years
measure: Mesh-associated complications
timeFrame: initial operation until an avarage of 3 years
Other outcomes:
Locations:
Study officials:
References:
citation: Ammann Y, Widmann B, Sparn M, Warschkow R, Weitzendorfer M, Brunner W. Prophylactic funnel mesh to prevent parastomal hernia in permanent end colostomy: A retrospective cohort study. Colorectal Dis. 2021 Oct;23(10):2627-2636. doi: 10.1111/codi.15817. Epub 2021 Sep 4.
Clinical trial NCT01682109: Palatability Testing of a New Paediatric Formulation of Valacyclovir
Official title: Palatability Testing of a New Paediatric Formulation of Valacyclovir for the Prophylaxis and Treatment of VZV and HSV Infections in Children
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Varicella Zoster Virus Infection
Herpes Simplex Virus Infection
Keywords: prophylaxis
herpes zoster
herpes simplex
valacyclovir
palatability
paediatric
Lead sponsor: Radboud University Medical Center
Sponsor class: OTHER
Collaborators: name: ZonMw: The Netherlands Organisation for Health Research and Development
First posted: 2012-09-10
Enrollment: 41
Sex: ALL
Minimum age (years): 4
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: Palatability testing of a new paediatric formulation of valacyclovir in children 4-12 years of age and at least one of their parents. Children will be included, who received (val)acyclovir prophylaxis in the past, or will probably need it in the future i.e. children with primary immune deficiency or cancer.


Eligibility criteria: Inclusion Criteria:

* Subject is at least 4 years of age.
* Subject weighs at least 15kg.
* Subject is capable of performing the taste assessment, according to the investigator's judgement.
* The child and parent(s) are willing to participate in the taste assessment.
* Signed informed consent by the legal guardian for participation of the child and if the parent also wants to participate: signed informed consent for their own participation, prior to start of the study.

Exclusion Criteria:

* Documented history of sensitivity/idiosyncrasy to medicinal products or excipients.
* Presence of any condition that influences taste sensation (such as upper respiratory infection, febrile illness within 3 days before the first dose, mucositis or use of medication that influences taste perception, as described in the label information).

Primary outcomes:
measure: Selection of oral solution with best taste
timeFrame: Day 1
Secondary outcomes:
measure: Taste assessment
timeFrame: Day 1
measure: Predictability of palatability preference of the child by parents.
timeFrame: Day 1
Other outcomes:
Locations:
city: Nijmegen
country: Netherlands
facility: Radboud University Medical Center
Study officials:
affiliation: Radboud University Medical Center
name: David Burger
role: PRINCIPAL_INVESTIGATOR
References:
citation: Bastiaans DET, Immohr LI, Zeinstra GG, Strik-Albers R, Pein-Hackelbusch M, van der Flier M, de Haan AFJ, Boelens JJ, Lankester AC, Burger DM, Warris A. In vivo and in vitro palatability testing of a new paediatric formulation of valaciclovir. Br J Clin Pharmacol. 2017 Dec;83(12):2789-2797. doi: 10.1111/bcp.13396. Epub 2017 Sep 20.
Clinical trial NCT01634256: A Human Trial to Evaluate the Efficacy and Safety of Fermented Turmeric in Subjects Showing Mild Hepatic Injury
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Mild Hepatic Injury
Lead sponsor: Chonbuk National University Hospital
Sponsor class: OTHER
First posted: 2012-07-06
Enrollment: 60
Sex: ALL
Minimum age (years): 19
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The investigators performed a double-blind parallel study in a group of showing mild hepatic injury subjects who were given Fermented turmeric over a period of 12 weeks. The investigators measured liver function parameters , including ALT(Alanine Transaminase), AST(Aspartate Transaminase), ALP(Alkaline Phosphatase), γ-GT(Gamma-Glutamyl Transferase), and serum bilirubin, and monitored their blood pressure.


Eligibility criteria: Inclusion Criteria:

* Males and females 19-70 years old
* Mild hepatic injury as indicated by ALT(Alanine Transaminase) level ≥ 40
* Able to give informed consent

Exclusion Criteria:

* Allergy or hypersensitivity to any of the ingredients in the test products
* History of reaction to any of the experimental products or of gastrointestinal diseases such as Crohn's disease or gastrointestinal surgery
* Carriers of viral hepatitis (type B and C)
* History of underlying Esophageal varices, hepatic encephalopathy, ascites(past 12 months)
* Participation in other clinical trials within the past 2 months
* Patients with acute hepatitis (type B and C)
* History of underlying cirrhosis and liver cancer
* History of underlying biliary diseases such as jaundice or gallstones
* History of underlying kidney disease such as Chronic renal failure or nephrotic syndrome
* Pregnant, planning to become pregnant, or breast-feeding
* Laboratory test, medical or psychological conditions deemed by the investigators to interfere with successful participation in the study

Primary outcomes:
measure: Changes in ALT(Alanine Transaminase)
timeFrame: 12 weeks
Secondary outcomes:
measure: Changes in AST(Aspartate Transaminase)
timeFrame: 12 weeks
measure: Changes in ALP(Alkaline Phosphatase)
timeFrame: 12 weeks
measure: Changes in γ-GT(Gamma-Glutamyl Transferase)
timeFrame: 12 weeks
measure: Changes in Serum Bilirubin
timeFrame: 12 weeks
Other outcomes:
Locations:
city: Jeonju
country: Korea, Republic of
facility: Clinical Trial Center for Functional Foods; Chonbuk National University Hospital
state: Jeollabuk-do
Study officials:
affiliation: Chonbuk National University Hospital
name: Sang-Wook Kim, MS
role: PRINCIPAL_INVESTIGATOR
References:
citation: Kim SW, Ha KC, Choi EK, Jung SY, Kim MG, Kwon DY, Yang HJ, Kim MJ, Kang HJ, Back HI, Kim SY, Park SH, Baek HY, Kim YJ, Lee JY, Chae SW. The effectiveness of fermented turmeric powder in subjects with elevated alanine transaminase levels: a randomised controlled study. BMC Complement Altern Med. 2013 Mar 8;13:58. doi: 10.1186/1472-6882-13-58.
Clinical trial NCT03989856: Effect of Laparoscopic Suturing Versus Bipolar Coagulation on Ovarian Reserve in Patients Undergoing Endometriotic Ovarian Cystectomy.
Official title: Effect of Laparoscopic Suturing Versus Bipolar Coagulation on Ovarian Reserve in Patients Undergoing Endometriotic Ovarian Cystectomy.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Ovary Injury
Lead sponsor: Ain Shams University
Sponsor class: OTHER
First posted: 2019-06-18
Enrollment: 60
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: The study population comprises females in childbearing period underwent laparoscopic ovarian cystectomy at Ain Shams University Maternity Hospital, Obstetric and Gynecology Department, Faculty of medicine.
Primary purpose: PREVENTION

Brief summary: In women undergoing laparoscopic ovarian cystectomy which is less harmfull on the ovarian reserve (electrocoagulation or suturing).

Detailed description: The aim of the present study was to determine which hemostatic procedure (hemostatic suture or electrocautery) may be less harmful after laparoscopic cystectomy, based on the longterm status of the ovarian reserve.

Eligibility criteria: Inclusion Criteria:

1. Age 18- 45.
2. Regular menstrual cycle.
3. Unilateral ovarian cyst clinical \& us finding as endometriotic cyst.
4. C/O of pelvic pain.
5. No medications (oral pills \& hormonal drugs) in the past 3 monthes before enrollement.
6. No evidence of endocrine disorders (DM, Thyroid dysfunction,hyper prolactenemia, congenital adrenal hyperplesia, cushing's syndrome or adrenal insufficiency)
7. No previous adnexial surgery.
8. Pathology diagnosis of excised ovarian tissue (endometriotic cyst)
9. Appropriate medical condition for laparoscopic surgery.
10. Completely understand the process of the study with written consent.

Exclusion Criteria:

1. PCO according to Rotterdam criteria.
2. Pathological diagnosis of excised ovarian tissue as non endometriotic cyst.
3. Previous ovarian surgery.
4. Suspected ovarian malignancy.
5. Patient whose histopathology showed benign cyst apart from endometrioma.
6. Irregular menstrual cycles.
7. Post menopausal status.
8. Bilateral ovarian cyst.
9. AMH \< 0.5 ng/ml.
10. Premature ovarian failure in family.

Primary outcomes:
measure: Ovarian reserve
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Ain shams maternity teaching hospital
state: Abbasia
Study officials:
affiliation: Ain Shams University
name: Mohamed Abd elfattah elsenitt, Lecturer
role: PRINCIPAL_INVESTIGATOR
References: